BRAF and malignant colon neoplasm: An important finding of this study was that CDC37 knockdown not only blocked rebound activation of Akt in mutant BRAF colon cancer cells after treatment with AUY922, but also inhibited constitutive activation of Akt in mutant but not wild-type BRAF colon cancer cells.